Shots:

• Noxopharm plans to seek approval to test its Veyonda (idronoxil) on COVID-19 patients in the US- following the research of Hudson Institute about the MOA of idronoxil that holds the potential to block STING signaling- which contributes to lethal self-destruction of major organs in patients with COVID-19
• The company is currently working with the FDA to obtain guidance on the regulatory approval pathway for pursuing the clinical study for COVID-19 patients in the US. Additionally- the company is pursuing the option to test Veyonda in patients with septic shock from infective agents other than the SARS-CoV-2 virus
• Indronoxil inhibits S1P & STING signaling pathways- currently being developed for end-stage PC. The company will evaluate the therapy in patients at risk of developing ARDS and multi-organ failure associated with COVID-19

Click here ­to­ read full press release/ article | Ref: Noxopharm | Image: Noxopharm